Denmark to India Pharmaceutical Import

The pharmaceutical trade corridor between Denmark and India has experienced significant growth from 2022 to 2026. In 2022, the total import value was approximately $150 million USD, with 1,200 shipments from 60 Danish suppliers to 50 Indian buyers. By 2026, these figures increased to a total import value of $226 million USD, 1,418 shipments, 71 Danish suppliers, and 61 Indian buyers. This growth reflects a strengthening bilateral trade relationship and India's increasing demand for high-quality pharmaceutical products.

Denmark has become a significant contributor to India's pharmaceutical imports, accounting for approximately 5% of India's total pharmaceutical imports in 2026. The primary categories imported from Denmark include insulin, semaglutide, and dapsone, which are essential for managing diabetes and other chronic conditions prevalent in India. These products are crucial in addressing India's healthcare needs, particularly in the management of non-communicable diseases.

Between 2024 and 2026, the Central Drugs Standard Control Organisation (CDSCO) implemented several policy changes to streamline the import process, including the introduction of digital registration systems for foreign pharmaceutical products. Additionally, India and Denmark engaged in bilateral discussions to enhance regulatory harmonization, aiming to simplify approval procedures and reduce time-to-market for imported drugs. These developments have facilitated smoother trade and increased the availability of essential medicines in India.

Danish pharmaceutical companies seeking to import products into India must register with the CDSCO. The process involves submitting an online application through the CDSCO's SUGAM portal, providing detailed product information, and ensuring compliance with Indian regulatory standards. Key requirements include obtaining a No Objection Certificate (NOC) from the CDSCO, which confirms that the product is approved for sale in Denmark and meets Indian safety and efficacy standards. The registration process typically takes 6 to 12 months, depending on the product category and completeness of the application.

India requires that imported pharmaceutical products adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Danish manufacturing sites must obtain WHO prequalification to demonstrate compliance with these standards. The CDSCO conducts inspections of foreign manufacturing facilities to verify adherence to GMP guidelines, ensuring that imported products meet India's quality and safety requirements.

To import pharmaceutical products into India, Danish companies must obtain an import license (Form 10) from the CDSCO. Additional required documents include a registration certificate, NOC, test license, and compliance with customs procedures. These documents ensure that imported products meet Indian regulatory standards and facilitate smooth customs clearance.

The dominant import categories from Denmark to India include insulin, semaglutide, and dapsone. Insulin and semaglutide are critical in managing diabetes, a major health concern in India. Dapsone is essential for treating leprosy and certain skin conditions. These products are often patented and not manufactured domestically, highlighting Denmark's role in supplying specialized medications to meet India's healthcare needs.

Denmark exports several innovator drugs and novel formulations to India, including biologics and advanced therapies for chronic diseases. These products are not manufactured domestically and are crucial in providing treatment options for conditions such as diabetes, rheumatoid arthritis, and certain cancers. Denmark's focus on research and development contributes to the availability of these specialized treatments in the Indian market.

India imports pharmaceutical products from Denmark due to several factors:

• Patent Protection: Denmark's strong intellectual property laws protect innovative drugs, ensuring exclusivity for manufacturers.

• Technology Gaps: India's pharmaceutical industry may lack the technology to produce certain advanced medications, necessitating imports.

• Quality Requirements: Denmark's adherence to high manufacturing standards aligns with India's demand for quality medicines.

• Disease Burden: The prevalence of chronic diseases in India increases the need for specialized treatments available from Denmark.

India imposes a basic customs duty on imported pharmaceutical formulations, with rates varying based on product classification. Additionally, an Integrated Goods and Services Tax (IGST) is levied on imports, and a health cess may apply to certain products. These tariffs are subject to change and are influenced by India's trade policies and international agreements.

India and Denmark have engaged in bilateral discussions to enhance trade relations, including the simplification of regulatory procedures for pharmaceutical imports. While there is no specific Free Trade Agreement (FTA) between the two countries, these efforts aim to reduce trade barriers and facilitate smoother market access for Danish pharmaceutical products.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under certain conditions, which can affect the pricing and availability of imported drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including those imported from Denmark, to ensure affordability for the Indian population.

Pharmaceutical products from Denmark to India are typically shipped via sea routes, with major ports such as Copenhagen and Aarhus serving as export points. Transit times vary depending on the shipping route and logistics arrangements but generally range from 20 to 30 days. Air freight is also utilized for time-sensitive shipments, with transit times of approximately 7 to 10 days.

Denmark's major export ports include Copenhagen and Aarhus, which are equipped to handle pharmaceutical shipments. In India, key import ports include Mumbai, Chennai, and Kolkata, which have facilities for handling pharmaceutical products, including cold chain logistics.

Indian customs procedures for pharmaceutical imports involve clearance by the Directorate General of Foreign Trade (DGFT) and the CDSCO. Imported pharmaceutical products are subject to testing by the CDSCO to ensure compliance with Indian standards. Cold chain management is critical for temperature-sensitive products, and compliance with Good Distribution Practice (GDP) is mandatory to maintain product efficacy and safety.

Despite being a major pharmaceutical manufacturer, India imports specialized and patented drugs from Denmark due to technology gaps, the need for high-quality products, and the prevalence of diseases that require advanced treatments not produced domestically. Denmark's expertise in producing such medications makes it a valuable partner in meeting India's healthcare needs.

Major Danish pharmaceutical companies, such as Novo Nordisk, have established a significant presence in India. These companies engage in direct sales, partnerships with local firms, and contract manufacturing to expand their market reach. Their strategies include adapting products to local needs, ensuring compliance with Indian regulations, and investing in local manufacturing capabilities.

India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic pharmaceutical manufacturing. While these efforts may reduce dependency on imports over time, the demand for specialized and high-quality pharmaceutical products from Denmark is expected to continue, albeit potentially at a reduced scale. The success of these initiatives will influence the future dynamics of pharmaceutical imports from Denmark to India.

India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Denmark's share in India's pharmaceutical imports is approximately 5%, with the USA and EU countries holding larger shares. However, Denmark's focus on high-quality and specialized products allows it to maintain a competitive position in the Indian market.

Indian buyers choose Danish pharmaceutical products due to Denmark's reputation for innovation, adherence to high manufacturing standards, strong patent protection, and established brand reputation. These factors contribute to the trust and preference for Danish products in the Indian market.

Indian manufacturers are increasingly developing alternatives to imported drugs, including biosimilars and generics, supported by the PLI scheme. While this may pose competition to imported products, the unique offerings and quality of Danish pharmaceuticals continue to provide a niche market segment. Ongoing innovation and adaptation to local needs will be crucial for maintaining Denmark's competitive edge in India.